GlassScriptPhysician profile
Gary L Fink
NPI 1134119738
$729.45
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $184.58 | 2019 | |
| Pfizer INC. | $113.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.23 | 2019 | |
| Astellas Pharma US INC | $56.47 | 2019 | |
| Merck Sharp & Dohme LLC | $50.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.46 | 2019 | |
| Glaxosmithkline, LLC. | $30.96 | 2019 | |
| Mylan Specialty L.P. | $27.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.28 | 2019 | |
| Lilly USA, LLC | $15.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.